Valuation : AstraZeneca PLC

Market Cap 245B 211B 198B 181B 338B 23,290B 339B 2,350B 908B 11,865B 919B 899B 37,589B P/E 2026 *
20.3x
P/E 2027 * 17.7x
Enterprise Value 264B 227B 214B 195B 365B 25,141B 366B 2,537B 981B 12,808B 992B 971B 40,576B EV / Sales 2026 *
4.17x
EV / Sales 2027 * 3.83x
Free-Float
96.63%
Yield 2026 *
2.12%
Yield 2027 * 2.26%
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 245B
+0.46%-2.32%+50.11%+90.20% 1,002B
-0.14%-4.10%+51.89%+64.15% 644B
+0.56%-3.02%+19.24%+69.32% 443B
-0.56%-3.03%+29.91%+36.16% 343B
+0.65%-14.45%+11.51%+27.21% 262B
+2.03%-3.06%-1.18%+12.11% 245B
-2.01%-13.61%+37.76%+46.60% 212B
-0.90%-5.06%-18.47%-58.14% 199B
-0.90%-4.79%+24.93%+86.89% 181B
Average -0.05%-5.00%+22.86%+41.61% 392.19B
Weighted average by Cap. +0.11%-4.24%+32.28%+56.35%

Financials

2026 *2027 *
Net sales 63.3B 54.47B 51.29B 46.73B 87.44B 6,023B 87.78B 608B 235B 3,069B 238B 233B 9,721B 66.9B 57.57B 54.2B 49.39B 92.41B 6,366B 92.77B 642B 248B 3,243B 251B 246B 10,274B
Net income 12.03B 10.35B 9.74B 8.88B 16.61B 1,144B 16.68B 115B 44.63B 583B 45.16B 44.18B 1,847B 13.77B 11.85B 11.15B 10.16B 19.02B 1,310B 19.09B 132B 51.1B 667B 51.7B 50.57B 2,114B
Net Debt 19.45B 16.74B 15.76B 14.36B 26.87B 1,851B 26.97B 187B 72.19B 943B 73.03B 71.45B 2,987B 11.77B 10.12B 9.53B 8.69B 16.25B 1,120B 16.32B 113B 43.67B 570B 44.18B 43.22B 1,807B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
157.80USD
Average target price
212.20USD
Spread / Average Target
+34.47%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!